Press Releases April 20, 2026 06:48 PM

Westport to Issue Q4 2025 and Full Year 2025 Financial Results on April 23, 2026

Westport to announce Q4 and full year 2025 financial results and host a conference call in April 2026

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
WPRT

Westport Fuel Systems Inc. announced it will release its Q4 and full year 2025 financial results on April 23, 2026, after market close, followed by a conference call and webcast on April 24, 2026. The company is a provider of advanced clean fuel technologies to support the transition to alternative energy solutions in transportation.

Westport to Issue Q4 2025 and Full Year 2025 Financial Results on April 23, 2026
WPRT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Westport specializes in alternative fuel, low-emission transportation technology including natural gas, renewable natural gas, and hydrogen.
  • The company supports OEMs and commercial transportation sectors in meeting regulatory and climate goals with cost-effective solutions.
  • Financial results for 2025 will be disclosed with an investor webcast and conference call planned.

VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- Westport Fuel Systems Inc. (TSX: WPRT / Nasdaq: WPRT) (“Westport” or “The Company”) announces that the Company will release 2025 financial results on Thursday, April 23, 2026, after market close. A conference call and webcast to discuss the financial results and other corporate developments will be held on Friday, April 24, 2026.

Time: 10:00 a.m. ET (7:00 a.m. PT)
Call Link: https://register-conf.media-server.com/register/BIefca98da5fb34b16a81dd15541e90b0c
Webcast: https://investors.westport.com

Participants may register up to 60 minutes before the event by clicking on the call link and completing the online registration form. Upon registration, the user will receive dial-in info and a unique PIN, along with an email confirming the details.

The webcast will be archived on Westport’s website and a replay will be available at https://investors.westport.com.

About Westport

Westport is a technology and innovation company connecting synergistic technologies to power a cleaner tomorrow. As a leading supplier of affordable, alternative fuel, low-emissions transportation technologies, we design, manufacture, and supply advanced components and systems that enable the transition from traditional fuels to cleaner energy solutions.

Our proven technologies support a wide range of clean fuels – including natural gas, renewable natural gas, and hydrogen – empowering OEMs and commercial transportation industries to meet performance demands, regulatory requirements, and climate targets in a cost-effective way. With decades of expertise and a commitment to engineering excellence, Westport is helping our partners achieve sustainability goals—without compromising performance or cost-efficiency – making clean, scalable transport solutions a reality.

Westport is headquartered in Vancouver, Canada. For more information, visit www.westport.com.

Investor Inquiries:
T: +1 604-718-2046
E: [email protected]


Risks

  • Market adoption of alternative fuel technologies may face regulatory or technological challenges affecting demand for Westport's products.
  • Uncertainties in the timing and impact of clean energy policies could influence the company’s financial results.
  • Competition in the clean transportation technology sector may impact market share and profitability.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026